JPRN-jRCT2071210134已完成1 期
A Clinical trial for Resminostat in Healthy Volunteers to Investigate the Effect of Food
Asami Tsubasa0 个研究点目标入组 12 人开始时间: 2022年3月17日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 45age old（—）
- 性别
- Male
入选标准
- •Caucasian males aged between 20 (inclusive) and 45 years of age (inclusive) at the time informed consent is obtained.
- •-Body Mass Index between 18.5 kg/m2 (inclusive) and 30.0 kg/m2 (inclusive) at the time informed consent is obtained.
- •-Written informed consent obtained from the subject.
排除标准
- •-Clinical significant medical history or concomitant disease of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder.
- •-History of surgery, such as gastrectomy, gastrointenstinal suture, or intenstinal resection that would potentially alter absorption of drugs. However, the history of appendicectomy is acceptable.
- •-History of clinically significant hypersensitivity or allergy to any drugs or foods.
研究者
相似试验
未知
1 期
A Phase I Study in Resminostat monotherapy and S-1/Resminostat therapy in Patients with biliary tract or pancreatic cancerJPRN-jRCT2080222812Yakult Honsha Co., Ltd.44
已完成
4 期
A prospective, randomized, controlled trial of retransfusion of intra-operatively collected filtered whole blood in total hip surgery.retransfusion of autologous bloodSangvia Blood Management System10043413NL-OMON33014AstraTech AB150
已完成
不适用
A randomised placebo-controlled trial of rivastigmine in delirium in older medical in-patients: a pilot studyDeliriumISRCTN27327721South Manchester University Hospitals NHS Trust (UK)50
尚未招募
3 期
Role of Rasontail matra basti in Anovulatory cycleCTRI/2020/12/030096swati pathade
进行中（未招募）
不适用
Phase II clinical study for the therapy of cystic fibrosis patients with aspecific mutatioCystic fibrosis patients with F508del-CFTR in homozygous or compound heterozygous with Class I or II mutationsEUCTR2013-001258-82-ITEuropean Institute for Cystic Fibrosis Research (IERFC)